Should I buy or sell IO Biotech stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IO Biotech in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IOBT shares. View IOBT analyst ratings or view top-rated stocks .

What is IO Biotech's stock price target for 2024?

3 equities research analysts have issued 12-month price objectives for IO Biotech's shares. Their IOBT share price targets range from $7.00 to $10.00. On average, they predict the company's stock price to reach $8.33 in the next twelve months. This suggests a possible upside of 463.1% from the stock's current price. View analysts price targets for IOBT or view top-rated stocks among Wall Street analysts .

How have IOBT shares performed in 2024?

IO Biotech's stock was trading at $1.88 on January 1st, 2024. Since then, IOBT shares have decreased by 21.3% and is now trading at $1.48. View the best growth stocks for 2024 here .

Are investors shorting IO Biotech?

IO Biotech saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 68,200 shares, a drop of 16.4% from the March 15th total of 81,600 shares. Based on an average daily trading volume, of 138,300 shares, the short-interest ratio is presently 0.5 days. Currently, 0.2% of the shares of the company are short sold. View IO Biotech's Short Interest .

When is IO Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our IOBT earnings forecast .

How were IO Biotech's earnings last quarter?

IO Biotech, Inc. (NASDAQ:IOBT) posted its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.04.

When did IO Biotech IPO?

IO Biotech (IOBT) raised $111 million in an IPO on Friday, November 5th 2021. The company issued 7,150,000 shares at $14.00-$17.00 per share.

How do I buy shares of IO Biotech?

Shares of IOBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IOBT

IO Biotech (IOBT) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free IOBT Stock Alerts

$1.48

+0.01 (+0.68%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.42
▼
$1.56
50-Day Range: $1.47
▼
$1.82
52-Week Range: $0.82
▼
$2.64

Volume: 91,570 shs
Average Volume: 94,648 shs
Market Capitalization: $97.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.33

Get IO Biotech alerts:

IO Biotech MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 463.1% Upside
$8.33 Price Target
Short Interest: Healthy
0.16% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.63
Based on 3 Articles This Week
Insider Trading: Selling Shares
$988,214 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.41) to ($1.36) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.32 out of 5 stars

Medical Sector

295th out of 911 stocks

Pharmaceutical Preparations Industry

128th out of 420 stocks

3.5

Analyst's Opinion

Consensus Rating
IO Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
IO Biotech has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.16% of the float of IO Biotech has been sold short.
Short Interest Ratio / Days to Cover
IO Biotech has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in IO Biotech has recently decreased by 16.42%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
IO Biotech does not currently pay a dividend.
Dividend Growth
IO Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IOBT.

2.6

News and Social Media Coverage

News Sentiment
IO Biotech has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for IO Biotech this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IO Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $988,214.00 in company stock.
Percentage Held by Insiders
Only 3.50% of the stock of IO Biotech is held by insiders.
Percentage Held by Institutions
54.76% of the stock of IO Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for IO Biotech are expected to grow in the coming year, from ($1.41) to ($1.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IO Biotech is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IO Biotech is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IO Biotech has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About IO Biotech Stock (NASDAQ:IOBT)

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

IOBT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IOBT Stock News Headlines

April 17, 2024 | msn.com

IO Biotech (IOBT) Price Target Decreased by 11.11% to 8.16

April 16, 2024 | americanbankingnews.com

IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decline in Short Interest

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 15, 2024 | globenewswire.com

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

April 11, 2024 | investing.com

IO Biotech presents cancer vaccine data at AACR

April 9, 2024 | globenewswire.com

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

April 5, 2024 | globenewswire.com

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

March 7, 2024 | finance.yahoo.com

IO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical Trials

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 6, 2024 | markets.businessinsider.com

Buy Recommendation for IO Biotech on Strong Data Prospects and Undervalued Stock Position

March 6, 2024 | morningstar.com

IO Biotech Inc IOBT

March 6, 2024 | msn.com

IO Biotech GAAP EPS of -$0.40 misses by $0.02

March 6, 2024 | globenewswire.com

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

March 5, 2024 | investorplace.com

IOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023

March 5, 2024 | globenewswire.com

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

February 26, 2024 | globenewswire.com

IO Biotech to Present at 44th Annual Cowen Health Care Conference

February 4, 2024 | msn.com

What's Next for Iovance Biotherapeutics Stock?

January 15, 2024 | finance.yahoo.com

IO Biotech, Inc. (NASDAQ:IOBT) most popular amongst private equity firms who own 61% of the shares, institutions hold 24%

January 3, 2024 | seekingalpha.com

IO Biotech: A Phase 3 Company Getting No Respect

December 21, 2023 | finance.yahoo.com

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

December 19, 2023 | finance.yahoo.com

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

November 27, 2023 | msn.com

IO Biotech executive discloses purchase of 10K shares

November 24, 2023 | seekingalpha.com

IOBT IO Biotech, Inc.

November 15, 2023 | investing.com

IO Biotech earnings beat, revenue was in line with estimates

November 15, 2023 | markets.businessinsider.com

Promising Clinical Trials and Favorable Safety Profile Drives Buy Rating for IO Biotech

November 14, 2023 | benzinga.com

IO Biotech Stock (NASDAQ:IOBT) Earnings Dates and Earning Calls

November 13, 2023 | msn.com

IO Biotech GAAP EPS of -$0.43 misses by $0.10

See More Headlines

Receive IOBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IO Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:IOBT
CUSIP: N/A
CIK: 1865494
Web: www.iobiotech.com
Phone: 45-7070-2980
Fax: N/A
Employees: 68
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.33
High Stock Price Target: $10.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +463.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-86,080,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -66.28%
Return on Assets: -59.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.37
Quick Ratio: 9.37

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.02 per share
Price / Book: 0.73

Miscellaneous

Outstanding Shares: 65,880,000
Free Float: 63,575,000
Market Cap: $97.50 million
Optionable: Not Optionable
Beta: 0.50

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Mai-Britt Zocca Ph.D. (Age 56)
Founder, President, CEO, Principal Financial Officer & Director
Comp: $733.88k
Ms. Amy B. Sullivan M.B.A. (Age 54)
Chief Financial Officer
Comp: $391.24k
Prof. Inge Marie Svane M.D.
Ph.D., Founder & Clinical Advisor
Prof. Mads Hald Andersen M.D.
Ph.D., Founder & Scientific Advisor
Anders Ljungqvist
Founder
Prof. Per Thor Straten
Founder
Mr. Eric Faulkner M.B.A.
Chief Technical Officer
Mr. Devin Whittemore Smith (Age 56)
Secretary, General Counsel & Chief Compliance Officer
Mr. Daniel G. Mannix Ph.D.
Senior Vice President of Regulatory Affairs
Ms. Diane McDowell Ph.D.
Senior Vice President of Clinical Development & Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IOBT Stock Analysis - Frequently Asked Questions

Should I buy or sell IO Biotech stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IO Biotech in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IOBT shares.
View IOBT analyst ratings or view top-rated stocks.
What is IO Biotech's stock price target for 2024?: 3 equities research analysts have issued 12-month price objectives for IO Biotech's shares. Their IOBT share price targets range from $7.00 to $10.00. On average, they predict the company's stock price to reach $8.33 in the next twelve months. This suggests a possible upside of 463.1% from the stock's current price.
View analysts price targets for IOBT or view top-rated stocks among Wall Street analysts.
How have IOBT shares performed in 2024?: IO Biotech's stock was trading at $1.88 on January 1st, 2024. Since then, IOBT shares have decreased by 21.3% and is now trading at $1.48.
View the best growth stocks for 2024 here.
Are investors shorting IO Biotech?: IO Biotech saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 68,200 shares, a drop of 16.4% from the March 15th total of 81,600 shares. Based on an average daily trading volume, of 138,300 shares, the short-interest ratio is presently 0.5 days. Currently, 0.2% of the shares of the company are short sold.
View IO Biotech's Short Interest.

When is IO Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our IOBT earnings forecast.
How were IO Biotech's earnings last quarter?: IO Biotech, Inc. (NASDAQ:IOBT) posted its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.04.
When did IO Biotech IPO?: IO Biotech (IOBT) raised $111 million in an IPO on Friday, November 5th 2021. The company issued 7,150,000 shares at $14.00-$17.00 per share.
How do I buy shares of IO Biotech?: Shares of IOBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IOBT) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

IO Biotech (IOBT) Stock Price, News & Analysis

IO Biotech MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About IO Biotech Stock (NASDAQ:IOBT)

IOBT Stock Price History

IOBT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

IOBT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™